DYADIC INTERNATIONAL INC (DYAI) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 3.80M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 3.18M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $3.80M | $3.18M | (m) |
| 2026-03-31 | (m) | $3.81M | $2.81M | (m) |
| 2025-12-31 | (m) | $3.09M | $2.32M | (m) |
| 2025-09-30 | (m) | $3.34M | $2.29M | (m) |
| 2025-06-30 | (m) | $4.14M | (m) | (m) |
| 2025-03-31 | (m) | $3.55M | (m) | (m) |
| 2024-12-31 | (m) | $3.50M | $1.19M | (m) |
| 2024-09-30 | (m) | $3.36M | $1.19M | (m) |
| 2024-06-30 | (m) | $1.80M | $901.90K | (m) |
| 2024-03-31 | (m) | $2.26M | $1.39M | (m) |
| 2023-12-31 | (m) | $2.90M | $1.98M | (m) |
| 2023-09-30 | (m) | $2.96M | $2.33M | (m) |
| 2023-06-30 | (m) | $3.44M | $2.83M | (m) |
| 2023-03-31 | (m) | $3.26M | $2.45M | (m) |
| 2022-12-31 | (m) | $2.93M | $2.12M | (m) |
| 2022-09-30 | (m) | $2.50M | $1.75M | (m) |
| 2022-06-30 | (m) | $2.31M | $1.54M | (m) |
| 2022-03-31 | (m) | $190.31M | $15.93M | (m) |
| 2021-12-31 | (m) | $2.40M | $1.94M | (m) |
| 2021-09-30 | (m) | $2.44M | $1.87M | (m) |
| 2021-06-30 | (m) | $2.16M | $1.74M | (m) |
| 2021-03-31 | (m) | $1.75M | $1.54M | (m) |
| 2020-12-31 | (m) | $1.60M | $1.42M | (m) |
| 2020-09-30 | (m) | $1.69M | $1.59M | (m) |
| 2020-06-30 | (m) | $1.73M | $1.71M | (m) |
| 2020-03-31 | (m) | $1.59M | $1.41M | (m) |
| 2019-12-31 | (m) | $1.68M | $1.46M | (m) |
| 2019-09-30 | (m) | $1.93M | $1.54M | (m) |
| 2019-06-30 | (m) | $1.74M | $1.40M | (m) |
| 2019-03-31 | (m) | $1.51M | $1.21M | (m) |
| 2018-12-31 | (m) | $1.30M | $1.03M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $758.42K | $680.20K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |